Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/ RenTCR-mimicTM ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery. Through our sub-brand, RenBiologics™, Biocytogen has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Currently, we have more than 40 assets in various stages from preclinical (PCC) to Investigational New Drug (IND) applications. Biocytogen offers flexible licensing and collaboration models for our antibody assets and RenMice platforms. As of June 30, 2024, 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs).
Company Details
- Founded
- -
- Address
- 300 3rd Ave,
- Industry
- Biotechnology
- Website
- https://renmab.com/
- HQ
- Waltham, Massachusetts
Renbiologics Questions
Renbiologics's website is https://renmab.com/
Renbiologics's LinkedIn profile is https://www.linkedin.com/company/renbiologics
Renbiologics's industry is
Biotechnology
Renbiologics's top competitors are
New Perspectives, Inc.,
Hope Medicine Inc,
Mirabiologics Inc.,
Rezq Bio,
Quad.bio,
Telesis Therapeutics, Inc.,
Mc Sciences,
Bionova Pharmaceuticals (Shanghai) Limited,
Novamab,
Biocytogen.
Renbiologics's categories are Biotechnology
Renbiologics's founding year is 2009
